Department for Continuing Education, Oxford University, Oxford, UK
Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, UK.
BMJ Open. 2022 Jul 8;12(7):e062154. doi: 10.1136/bmjopen-2022-062154.
Failure to recognise and respond to patient deterioration in an appropriate and timely manner has been highlighted as a global patient safety concern. Early Warning Scores (EWSs) using vital signs were introduced to address this concern, with the aim of getting the patient timely and appropriate treatment. The National Early Warning Score 2 (NEWS2) is in use across the NHS, and many other settings globally. While patient improvements have been shown, research has identified that the NEWS2 is not always used as intended. Therefore, this review will use a realist approach to understand what the mechanisms are that influence appropriate use (or not) of the NEWS2 in acute care settings, how, for whom and in which contexts. The findings will inform clinicians of what helps and/or hinders appropriate use of the NEWS2 in clinical practice, thus helping to facilitate successful implementation.
Our realist review will follow Pawson's iterative six step process: (1) Development of initial programme theory. (2) Searching the literature; an information scientist will develop, pilot and refine the search strategy. A systematic search will be completed, based on subject relevancy on the following databases: Cumulative Index to Nursing and Allied Health Literature (CINAHL), Medline, Embase (OvidSP), Web of Science (Science Citation Index and Social Science Citation), Cochrane Database of Systematic Reviews, Joanna Briggs Institute, Ethos, Proquest Dissertations and Theses Global, and Google Scholar for documents dating from 1997 (date of the first published EWS) to present. To retrieve additional relevant data 'snowballing' (finding references and authors by hand, contacting authors, searching reference lists and citation-tracking using Google Scholar) will be used. Inclusion criteria include all documents (including grey literature) that relate to the use of EWSs/NEWS2 in the English language only. Documents set in the paediatric, maternity and primary care settings will be excluded. (3) Selecting documents and quality appraisal. (4) Extracting and organising the data. (5) Synthesising the data. (6) Disseminating the findings. We will recruit a group of stakeholders comprised of experienced clinicians who use the NEWS2 as part of their clinical practice to provide feedback throughout the review. Step 1 has already begun with the development of an initial programme theory. This initial programme theory presents how the NEWS2 is supposed to work (or not), it will now be developed, tested and refined.
Ethical approval is not required for this study as it is secondary research. Dissemination will include a peer-reviewed publication and conference presentations. Findings will also be amplified through social media platforms with user friendly summaries. Our stakeholder group will also contribute to dissemination of findings in their clinical areas and among existing networks.
CRD42022304497.
未能及时、适当地识别和应对患者病情恶化已被强调为全球患者安全关注的问题。使用生命体征的早期预警评分(EWS)被引入以解决这一问题,目的是为患者提供及时、适当的治疗。国家早期预警评分 2 版(NEWS2)在英国国家医疗服务体系(NHS)和全球许多其他环境中使用。虽然已经证明患者的病情有所改善,但研究表明,NEWS2 并不总是按预期使用。因此,本综述将采用现实主义方法来了解影响急性护理环境中正确使用(或不使用)NEWS2 的机制是什么,以及如何、为谁以及在何种情况下使用。研究结果将为临床医生提供有关在临床实践中有助于或阻碍正确使用 NEWS2 的信息,从而有助于促进成功实施。
我们的现实主义综述将遵循 Pawson 的迭代六步过程:(1)制定初始方案理论。(2)搜索文献;信息科学家将开发、试验和完善搜索策略。将根据以下数据库的主题相关性完成系统搜索:护理与联合健康文献累积索引(CINAHL)、医学索引在线(Medline)、Embase(OvidSP)、Web of Science(科学引文索引和社会科学引文索引)、考科蓝循证医学数据库、乔安娜布里格斯研究所、ProQuest 论文与学位全球数据库和 Google Scholar,文献日期为 1997 年(首次发表 EWS 日期)至现在。为了检索额外的相关数据,将使用“滚雪球”(通过手工查找参考文献和作者、联系作者、搜索参考文献列表和使用 Google Scholar 进行引文跟踪)。纳入标准包括所有与 EWS/NEWS2 在英语中的使用相关的文档(包括灰色文献)。儿科、产科和初级保健环境中的文献将被排除在外。(3)选择文献和质量评估。(4)提取和组织数据。(5)综合数据。(6)传播研究结果。我们将招募一组由经验丰富的临床医生组成的利益相关者,他们将 NEWS2 作为其临床实践的一部分,以便在整个审查过程中提供反馈。第 1 步已经开始,制定了初始方案理论。这个初始的方案理论展示了 NEWS2 应该如何运作(或不运作),现在将对其进行开发、测试和完善。
本研究不需要伦理批准,因为它是二次研究。传播将包括同行评议的出版物和会议演讲。研究结果还将通过用户友好的摘要在社交媒体平台上放大。我们的利益相关者群体还将在其临床领域和现有网络中为研究结果的传播做出贡献。
PROSPERO 注册号:CRD42022304497。